Technical weakness and oversold signals: NuCana stock falls 3.22%

Traders Union
All News
Financial News
NuCana slides 3.22% today to $1.66

Highlights

NUC-7738 displayed positive clinical activity and safety in Phase 2 for patients with PD-1 inhibitor-resistant melanoma.
NuCana cancelled all remaining Series A Warrants from its May 2025 financing for $3.6 million and advances its ProTide pipeline.
Technicals remain bearish with NCNA trading well below trend averages, high volatility, and a $1.54–$1.78 consolidation range likely as sellers dominate.

Pipeline updates and warrant cancellation as price extends losses

NuCana reported its financial results for the fourth quarter and full year ended December 31, 2025, alongside updates to its clinical development program. Final Phase 2 expansion data showed that NUC-7738 demonstrated clinical activity and favorable safety in patients with PD-1 inhibitor-resistant melanoma. In addition, on July 21, 2025, the company completed the cancellation of all remaining Series A Warrants issued in its May 2025 financing in exchange for $3.6 million, and NuCana continues to develop its ProTide pipeline with both NUC-7738 and NUC-3373, though price action has remained under broader selling pressure.

Persistent bearish momentum confirmed across oversold technicals

Momentum remains firmly negative, with the D1 MACD and ADX signaling a continued bearish trend. Both the RSI (29.72) and CCI (-211.65) indicate oversold conditions, echoed by the Stoch RSI at 0.00, yet BBP and AO confirm that sellers maintain dominance. The daily session opened nearly unchanged from the previous close, showing no gap, but the price has slipped 3.22% and is currently trading near today’s low, suggesting high intraday volatility and clear downside pressure after the open. All intraday and daily momentum signals reinforce the bearish tone with no significant divergence between oscillators and trend indicators.

Downside risk dominates as low rebound odds shape trading range

For the next five sessions, the expected trading range is adjusted to $1.54 – $1.78 to fit market volatility around the current price. The probability of an upward move is very low (less than 20%), making a decline much more likely. Baseline scenario: price holds within the $1.54 – $1.78 band, consolidating near recent lows. Bullish scenario: a move above immediate resistance at $1.95 triggers a short-term rebound, while a break below $1.54 opens the way for further downside and sustained seller control.

Anton Kharitonov, expert at Traders Union, sees NuCana’s technical setup as heavily bearish, with the price pinned below all major moving averages and firm negative momentum. He notes that despite recent clinical updates and progress in the pipeline, market sentiment continues to favor sellers. The base case is continued consolidation within $1.54 – $1.78, with downside risk dominating the outlook. "Unless the price can reclaim $1.95, any upside attempts are likely to fail and I remain defensively positioned here."

Earlier, analysts noted that NuCana remained under sustained technical pressure with persistent bearish momentum dominating across multiple timeframes. The latest analysis strengthens this view as all momentum signals reinforce downside risk, positioning $1.54 as the critical support level to monitor for a potential further decline.

Source of Data: NCNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.